- Title
- Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
- Creator
- Zhai, Jiali; Luwor, Rodney; Ahmed, Nuzhat; Escalona, Ruth; Tan, Fiona; Fong, Celesta; Ratcliffe, Julian; Scoble, Judith; Drummond, Calum; Tran, Nhiem
- Date
- 2018
- Type
- Text; Journal article
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/167665
- Identifier
- vital:13715
- Identifier
-
https://doi.org/10.1021/acsami.8b08125
- Identifier
- ISBN:1944-8244
- Abstract
- Chemotherapy using cytotoxic agents, such as paclitaxel (PTX), is one of the most effective treatments for advanced ovarian cancer. However, due to nonspecific targeting of the drug and the presence of toxic solvents required for dissolving PTX prior to injection, there are several serious side effects associated with this treatment. In this study, we explored self-assembled lipid-based nanoparticles as PTX carriers, which were able to improve its antitumour efficacy against ovarian cancer. The nanoparticles were also functionalized with epidermal growth factor receptor (EGFR) antibody fragments to explore the benefit of tumor active targeting. The formulated bicontinuous cubic- and sponge-phase nanoparticles, which were stabilized by Pluronic F127 and a lipid poly(ethylene glycol) stabilizer, showed a high capacity of PTX loading. These PTX-loaded nanoparticles also showed significantly higher cytotoxicity than a free drug formulation against HEY ovarian cancer cell lines in vitro. More importantly, the nanoparticle-based PTX treatments, with or without EGFR targeting, reduced the tumor burden by 50% compared to PTX or nondrug control in an ovarian cancer mouse xenograft model. In addition, the PTX-loaded nanoparticles were able to extend the survival of the treatment groups by up to 10 days compared to groups receiving free PTX or nondrug control. This proof-of-concept study has demonstrated the potential of these self-assembled lipid nanomaterials as effective drug delivery nanocarriers for poorly soluble chemotherapeutics, such as PTX.
- Publisher
- American Chemical Society
- Relation
- ACS Applied Materials & Interfaces Vol. 10, no. 30 (2018), p. 25174-25185
- Rights
- Copyright © 2018 American Chemical Society.
- Rights
- This metadata is freely available under a CCO license
- Subject
- 09 Engineering; 03 Chemical Sciences; Lipid nanoparticles; Ovarian cancer; Paclitaxel; Drug delivery; Cubosomes; Sponge nanoparticles; EGFR
- Reviewed
- Hits: 2905
- Visitors: 2787
- Downloads: 0